undamentalytics Newsletter
Sign in

Neuroone Medical Technologies Corp cash flow statement

In fiscal 2025, Neuroone Medical Technologies Corp's operations generated −$2.8m of cash; it spent $81,742 on capital projects, leaving free cash flow of −$2.9m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20102012Dec 20112013Dec 20122014Dec 20132015Dec 20142016Dec 20152017Dec 20162021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Cash from operations−0−0−0−0−0−0−0−9−8−13−11−3−7
Depreciation and amortisation———————000000
Stock-based pay———————211111
Capital spending———————000000
Free cash flow———————−9−8−13−11−3−7
Free cash flow after stock pay———————−10−9−14−12−4−9
Shares issued—0———————31——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: MLSS vs NMTCNMTC vs WOKNMTC vs NUWENMTC vs NNNN

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Neuroone Medical Technologies Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neuroone Medical Technologies Corp.